Buprenorphine Microdosing: Innovations in Opioid Overdose Prevention from the Front Lines

Dec 14, 2020 - 12:00pm to 1:00pm
Zoom - see below for details
Jessica Moe

Since the onset of the COVID-19 pandemic, overdose deaths have risen to unprecedented highs in British Columbia (BC), confirming the ongoing and heightened urgency of the public health crisis related to overdose deaths.

This session will describe a research project aiming to expand access to buprenorphine/naloxone (Suboxone) from emergency departments (EDs) using a novel microdosing approach to inductions. ED buprenorphine increases retention in addictions care and decreases illicit drug use among patients with opioid use disorder. Yet, barriers prevent widespread uptake in Canadian EDs, including patient discomfort associated with standard dosing approaches. Microdosing, a novel approach seeking to improve patient comfort, could mitigate many barriers to buprenorphine/naloxone initiation.

Learning Objectives:

  1. Recognize the importance of emergency departments as key locations to identify people at risk for overdose and to offer preventative interventions;
  2. Recognize the importance of designing interventions that minimize access barriers in the public health response to the opioid overdose crisis.

Zoom Details:


Meeting ID: 898 1262 3971
Passcode: mxFY0M

One tap mobile
+14388097799,,89812623971#,,,,,,0#,,261430# Canada
+15873281099,,89812623971#,,,,,,0#,,261430# Canada

Dial by your location
        +1 438 809 7799 Canada
        +1 587 328 1099 Canada
        +1 647 374 4685 Canada
        +1 647 558 0588 Canada
        +1 778 907 2071 Canada
        +1 204 272 7920 Canada

Meeting ID: 898 1262 3971
Passcode: 261430

Find your local number: https://us02web.zoom.us/u/kczTY6Ex4s